Abstract：Objective To investigate the efficacy and safety of Doxorubicin Liposome in the prevention of postoperative recurrence of bladder cancer by intravesical instillation.Methods A total of 75 patients with superficial bladder cancer who were treated in our hospital from February 2013 to March 2015 were selected as the study subjects.They were divided into the control group(37 cases)and the treatment group(38 cases)according to the sequential order of surgery.The control group was given Pirarubicin bladder infusion,and the treatment group was given Doxorubicin Liposome bladder infusion method.The recurrence rate and the total incidence rate of adverse reactions were compared between the two groups.Results The follow-up period was 2 years.The recurrence rate 24 months after treatment in the treatment group was 18.42%,which was lower than that in the control group (35.14%),and the difference was statistically significant(P＜0.05).The total incidence rate of adverse reactions in the treatment group was 26.31%,which was lower than that in the control group(62.16%),and the difference was statistically significant(P＜0.05).ConclusionIntravesical instillation of Doxazosin Liposomes is effective in the prevention of postoperative recurrence of bladder cancer.
杨荣辰;薛刚. 多柔比星脂质体膀胱灌注预防膀胱癌术后复发的临床研究[J]. 中国当代医药, 2018, 25(29): 64-66.
YANG Rong-chen;XUE Gang. Clinical study of intravesical instillation of Doxorubicin Liposomes in the prevention of postoperative recurrence of bladder cancer. 中国当代医药, 2018, 25(29): 64-66.
Klan R，Loy V，Huland H.Residual tumur discovered inroutine second transurethral resection in patients with stage T1transitional cell carcinoma of the bladder[J].J Urol，2015，170（2）：316-318.
[3]
Herr HW.The value of a second transurethral resection inevaluating patients with bladder tumers[J].J Urol，1999，162（1）：74-76.
[4]
Kolozsy Z.Histopathological“self control”in transurethral resection of bladder tumers[J].Bju Int，2016，73（2）：162-164.[5]Schenk-Braat EA，Bangmach T.Immunotherapy for superficial bladder cancer[J].Cancer Immunol Immunother，2005，54（5）：414-423.
[6]
Sylvester RJ，Osterlinck W，Witjes J.The schedule and duration of intravesical chemotherapy in patients with non muscle invasive bladder cancer：a systematic review of the published results of randomized clinical trials[J].Eur Urol，2017，153（4）：709-719.
Peng GH，Wei Q，Guan J，et al.A systematic review of epirubicin for prevention of postoperative recurrence of superficial bladder cancer[J].Chin J Evidence-Based Med，2016，14（6）：382-388.
[10]
Matamura Y，Tsushima T，Ozaki Y，et al.Intravesical chemotherapy with 4′-epiadriamycin in patients with superficial bladder tumours[J].Cancer Chemother Pharmacol，2016，9（8）：323-325.
[11]
Theodoulou M，Hudis C.Cardiac profiles of liposomal anthracyclines：greater cardiac safety versus conventional doxorubicin[J].Cancer，2015，100（10）：2052-2063.
[12]
Bielack SS，Erttmann R，Kempf-Bielack B，et al.Impact of scheduling on toxicity and clinical efficacy of Doxorubicin：what do we know in the mid-nineties?[J].Eur J Cancer，2006，52（10）：1652-1660.
[13]
Matsumura Y，Maeda H.A new concept for macromolecular therapeutics in cancer chemotherapy：mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs[J].Cancer Res，2016，46（12）：6387-6392.
京公网安备 11010502046607号